Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed/refractory multiple myeloma
Background In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
LJ Costa, Y Lin, RF Cornell, T Martin… - … Myeloma & Leukemia, 2021 - europepmc.org
Background In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
LJ Costa, Y Lin, RF Cornell, T Martin… - Clinical Lymphoma …, 2022 - profiles.wustl.edu
Background: In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
LJ Costa, Y Lin, RF Cornell, T Martin… - Clinical lymphoma …, 2022 - pubmed.ncbi.nlm.nih.gov
Background In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
LJ Costa, Y Lin, RF Cornell… - Clinical …, 2022 - mayoclinic.elsevierpure.com
Background: In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
LJ Costa, Y Lin, RF Cornell… - Clinical …, 2021 - utsouthwestern.elsevierpure.com
Background: In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
LJ Costa, Y Lin, RF Cornell… - Clinical …, 2022 - clinical-lymphoma-myeloma …
Background In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
LJ Costa, Y Lin, RF Cornell… - Clinical …, 2022 - clinical-lymphoma-myeloma …
Background In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …